Third-Party Assurance

 The data marked with has been assured by KPMG AZSA Sustainability Co., Ltd. in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information, and ISAE 3410, Assurance Engagements on Greenhouse Gas Statements, issued by the International Auditing and Assurance Standards Board (IAASB).

Independent Practitioner's Limited Assurance Report

Environmental Data

All environmental data is reported on a global basis, covering Daiichi Sankyo (non-consolidated) and all its consolidated subsidiaries unless otherwise specified.

Climate Change

Classification Unit FY2023 FY2024 FY2025 Assured (FY2025)
CO2 emissions Scope 1＊1 t-CO2 85,245 91,836 79,150
Scope 2(market-based) ＊1 t-CO2 23,994 24,477 24,585
Scope 1+2(market-based) ＊1 t-CO2
 109,239 116,312 103,735  
Scope 3＊2 t-CO2e 4,408,736 4,159,664 4,288,164
Scope 3 Category 1＊2 t-CO2e 3,887,790 3,549,346 3,532,693

GHG emissions quantification is subject to uncertainty when measuring activity data, determining emission factors, and considering scientific uncertainty inherent in the global warming potentials.

Energy

Classification Unit FY2023 FY2024 FY2025 Assured (FY2025)
Breakdown of energy use*3 Electricity (excluding renewable electricity) MWh 51,260 53,045 57,267
Renewable electricity MWh 204,554 210,896 225,142
Electricity total MWh 255,814 263,941 282,409  
Renewable electricity utilization rate ％ 80.0 79.9 79.7
City gas MWh 406,901 375,525 349,400
Others (LPG, LNG, heavy oil, kerosene, diesel oil, gasoline) MWh 58,881 63,875 54,816
Other renewable energy MWh 15,192 16,330 17,957
Total MWh 736,789 719,671 704,582

Water resources

Classification Boundary Unit FY2023 FY2024 FY2025 Assured (FY2025)
Water used
(municipal water, industrial water, fresh ground water)		 Plants and research facilities 1,000 m3 8,191 8,060 8,016
Wastewater discharge (public ｗater, sewer)＊4 Plants and research facilities 1,000 m3 8,232 8,078 8,333
Effective water usage volume＊5＊6 1,000 m3 -41 -18 -317
COD＊7 Plants and research facilities that discharge wastewater into public waters t 15 15 16

Waste*8

Classification Boundary Unit FY2023 FY2024 FY2025 Assured (FY2025)
Total amount of waste discharged Plants and research facilities t 10,909 13,371 9,245
Total amount of waste discharged
(excluding hazardous waste)＊9		 Plants and research facilities t 5,435 10,223 5,476
Recycled waste Plants and research facilities t 2,744 2,765 2,811
Final disposal Plants and research facilities t 1,180 6,602 1,158
Disposal of hazardous waste Plants and research facilities  t 5,474 3,148 3,769  
Waste plastic generated＊10 Plants and research facilities  t  651 672 615  
  Waste attributable to DAIICHI SANKYO
  t  487 514 455  
  Waste attributable to DAIICHI SANKYO BIOTECH 
  t 105 71 67  
Waste plastic recycling rate＊10 Plants and research facilities % 72.4 77.8 79.6

Air

Classification Boundary Unit FY2023 FY2024 FY2025 Assured (FY2025)
SOx emissions Plants and research facilities t 0.8 0.4 0.3
NOx emissions Plants and research facilities t 46 31 31
 
  • ＊1Scope 1: For domestic sites, the emission factors stipulated by the Act on Promotion of Global Warming Countermeasures are used. For overseas sites, the emission factors stipulated by each country's laws and regulations are generally applied. Where specific factors are unavailable, emission factors stipulated by the Act on Promotion of Global Warming Countermeasures are used.
  • Scope 2: The emission factors are determined by the power contract or each country's laws and regulations. When renewable energy or renewable energy certificates are used, an emission factor of zero is applied.
  • ＊2Emission Intensity Database for Calculating Greenhouse Gas Emissions of Organizations through Supply Chains provided by Ministry of the Environment is used.  
  • ＊3Fuel consumption is calculated mainly using the heat values per unit defined by the U.S. Environmental Protection Agency (EPA).
  • ＊4The increase in discharge volumes in FY2025 was attributable to flow meter malfunctions at a site in Japan, where discharge volumes were estimated for part of the reporting period.
  • ＊5Water used - Wastewater discharge
  • ＊6Due to a Japanese site measuring rainwater amount flowing into wastewater ditches, the amount of wastewater discharge exceeds the water used.
  • ＊7COD pollution in Japan is the sum of measurements at four sites in Japan (Tatebayashi site, Onahama site, Odawara site and Kitamoto site) with potassium permanganate as an oxidant. The global COD pollution load represents the total of Japan and overseas, with the overseas figures measured by the colorimetric determination method.
  • ＊8Excludes DSI San Diego in the U.S.
  • ＊9The figure in FY2024 includes the waste temporarily generated by the soil remediation at Odawara Plant.
  • ＊10Excludes Waste Plastic Generated in the U.S.

Third-Party Assurance

The data marked with has been assured by KPMG AZSA Sustainability Co., Ltd. in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information, issued by the International Auditing and Assurance Standards Board (IAASB). 

Independent Practitioner's Limited Assurance Report

Social Data

Number of employees＊1

　　　　
Boundary＊2 Items Unit FY2023 FY2024 FY2025 Assured(FY2025)
Global Total Persons 18,726＊3 19,765＊3 20,171＊3
Female Persons 7,683 8,459 8,764
％ 41.0 42.8 43.4
Male Persons 11,037 11,297 11,397
％ 58.9 57.2 56.5
Japan Total Persons 9,468 9,362 9,531
Female Persons 2,615 2,711 2,871
％ 27.6 29.0 30.1
Male Persons 6,853 6,651 6,660
％ 72.4 71.0 69.9
Outside Japan Total Persons 9,258＊3 10,403＊3 10,640＊3
Female Persons 5,068 5,748 5,893
％ 54.7 55.3 55.4
Male Persons 4,184 4,646 4,737
％ 45.2 44.7 44.5
By region (Outside Japan) North America Persons 3,573 4,025 4,098
Europe Persons 2,901 3,367 3,468
Asia-Pacific Persons 2,161 2,356 2,372
South and Central America Persons 623 655 702
Japan Number of temporary employees Persons 693 641 665

Employment Data

Classification Boundary＊2 Items Unit FY2023 FY2024 FY2025 Assured(FY2025)
Number of new employees Global Total Persons 2,840 2,513＊3 1,749＊3
Female Persons 1,560 1,318 777
Male Persons 1,280 1,161 970
Japan Total Persons 424 499 493
Female Persons 169 210 233
Male Persons 255 289 260
Outside Japan Total Persons 2,416 2,014＊3 1,256＊3
Female Persons 1,391 1,108 544
Male Persons 1,025 872 710
Number of new graduate employees Japan Total Persons 217
non-consolidated98		 247
non-consolidated108		 311
non-consolidated261
Female Persons 108 129 162
Male Persons 109 118 149
Number of mid-career hire employees Japan Total Persons 207
 252
 182
Female Persons 61 81 71
Male Persons 146 171 111
Proportion of mid-career hires＊4 Japan ％ 48.8
 50.5
 36.9
Total turnover rate Global Total ％ 5.6 6.0 6.1
Female ％ 6.6 6.2 6.9
Male ％ 5.0 5.7 5.0
Japan Total ％ 1.9 3.0 1.4
Turnover rate (due to personal reasons) Global Total ％ 3.7 4.1 4.1
Female % 4.7 4.1 4.7
Male ％ 3.0 3.9 3.3
Japan Total ％ 1.3 2.5 1.0
Retention rate of employees in their 3rd year of service Japan Total ％ 95.1 96.3 97.7
Female ％ 92.7 97.1 97.2
Male ％ 97.3 95.2 98.2
Average years of service Global Total Years 12.7 13.8 12.3
Female Years 8.7 8.8 8.9
Male Years 15.5 15.1 14.9
Japan Total Years 19.4 19.4 18.8
Female Years 15.1 15.1 14.4
Male Years 21.1 21.1 20.7
Outside Japan Total Years 5.6 6.0 7.0
Female Years 5.4 5.8 6.2
Male Years 6 6.2 6.6

Percentage of Women in Senior Management

Classification Boundary＊2 Items Unit FY2023 FY2024 FY2025 Assured(FY2025)
Proportion of senior managerial employees＊5 Global Female ％ 18.7 24.2 26.9
Japan Female ％ 8.2 11.4 12.0
Proportion of employees at managerial positions＊6 Daiichi Sankyo Company, Limited Female % 11.3 14.2 15.3

Work-Life Balance

Classification Boundary＊2 Items Unit FY2023 FY2024 FY2025 Assured(FY2025)
Rate of paid vacation usage Japan Total ％ 84.9 87.6 85.9
Number of employees taking childcare leave Japan Female Persons 87 92 99
% 106 86 107
Male Persons 123 119 188
Outside Japan Female Persons 125 153 229
Male Persons 102 112 145
Return-to-work rate after childcare leave＊7 Japan Female ％ 100 99 100
Male ％ 100 100 99
Retention rate of employees after taking childcare leave＊8 Japan Female ％ 100 100 95
Male ％ 98 100 96
Number of employees taking nursing care leave Japan Female Persons 302 302 325
Male Persons 295 304 412
Number of employees taking long-term caregiver leave Japan Female Persons 0 2 0
Male Persons 2 4 3
Number of employees taking short-term caregiver leave Japan Female Persons 115 129 156
Male Persons 188 217 274

Employment rate of people with physical or mental disabilities

Boundary＊2 Unit FY2023 FY2024 FY2025 Assured(FY2025)
Japan ％ 2.57 2.59 2.67

Human resource development

Classification Boundary＊2 Unit FY2023 FY2024 FY2025 Assured(FY2025)
Number of company award winners＊9 Japan Persons 60 59 56
Average training hours per employee
 Japan Hours 57.5  73.7  71.5   
Amount of training/development investments per employee Global JPY 166,906 207,430 226,536
Positive response rate (%) on corporate culture & work environment through engagement survey Global ％ 79 76 77
Positive response rate (%) on development & growth opportunities through engagement survey Global ％ 76 77 78

Occupational health and safety

Classification Boundary＊2 Unit FY2023 FY2024 FY2025 Assured(FY2025)
Total hours worked in a year Japan Hours 1,857 1,904 1,891
Lost time injuries frequency rate＊10(Full-time employees, contract employees)＊11 Global ー 1.42 1.62 1.15
Japan ー 0.23 0.58 0.35
Outside Japan ー 2.69 2.60 1.84
Lost time injuries frequency rate＊10 (Temporary employees)＊12 Global ー 1.59 1.90 2.73
Occupational accident fatalities Global Persons 0 0 0
Accident severity rate＊13 Japan ー 0.0024 0.0012 0.0097  
Outside Japan ー 0.0570 0.0768 0.0349  
Global ー 0.0290 0.0403 0.0232  
 

Enhancement of Communication

 Aspect Boundary＊2 Unit  FY2023  FY2024  FY2025  Assured(FY2025)
Overall assessment of MRs＊14 All responding physicians Japan Rank 1st 1st 1st
Hospital doctors Japan Rank 1st 1st 1st
Private practitioner Japan Rank 1st 1st 1st
Number of inquiries received by the product information center from outside the company (prescription pharmaceuticals) Cases 60,000 60,000 60,000
Number of clinical trial summaries for patients (number of studies) Cases 12 11 9
Number of clinical trial results summaries for patients (number of studies) Cases 4 7 10
Political contributions/Lobby activity expenses Global JPY Million 59.3 90.4 68.7
Trade associations or tax-exempt groups Global JPY Million 956.9 1,378 857.4

Improving Access to Healthcare

Boundary＊2 Unit FY2023 FY2024 FY2025 Assured(FY2025)
Number of development projects conducted through the GHIT＊15 Aggregate (January to December) Cases 4 3 1

Social Contribution Activities

Boundary＊2 Unit FY2023 FY2024 FY2025 Assured(FY2025)
Amount of contributions Japan JPY Million 1,099 1,195 1,295
Number of visitors to our laboratories and plants Japan Persons 611 432 309
Charitable contributions and sponsorship Global JPY Million 1,783 2,122 2,193
Number of visitors to Kusuri (Medicine) Museum＊16 Non-consolidated Persons 9,358 10,556 11,131
Number of employees taking short-term volunteer leave Japan Persons 9 5 12
Number of employees taking long-term leave for volunteer activities Japan Persons 0 0 0
Number of employees taking leave for bone marrow donation Japan Persons 1 2 1
 
 
  • ＊1The numbers of employees means the total count of employees in all Group companies at the end of the fiscal year (as of March 31, 2026 for FY 2025). Average years of service is calculated based on the information as of April 1 of the next fiscal year.
  • ＊2Japan: Daiichi Sankyo (non-consolidated) and consolidated subsidiaries in Japan, Outside Japan: overseas consolidated subsidiaries, Global: Daiichi Sankyo (non-consolidated) and all its consolidated subsidiaries
  • ＊3Including non-binary category based on the requests
  • ＊4Percentage of mid-carrier employees to all regular employees was calculated based on the Comprehensive Labor Policy Promotion Act, published on October 1, 2025
  • ＊5Percentage of employees at the level of division head or above
  • ＊6Percentage of employees at the level of organization heads including divisions, departments, and groups, who are responsible for managing business performance and human resources
  • ＊7(Total number of employees returning to work after childcare leave / Total number of employees scheduled to return to work after childcare leave in the given fiscal year) × 100
  • ＊8(Total number of employees who continued to work for 12 months after returning to work after childcare leave / Total number of employees who returned to work after childcare leave in the previous fiscal year) × 100
  • ＊9Total number of employees who received a prize for culture-building and achievement awards
  • ＊10Number of work-related deaths and injuries/Total hours worked × 1,000,000 The number of work-related deaths and injuries counts cases that involved at least a day of leave
  • ＊11In FY2023, Outside Japan and Global excluded Daiichi Sankyo Australia, Daiichi Sankyo Singapore, and Daiichi Sankyo Canada. In FY2024, Outside Japan and Global excluded Daiichi Sankyo Australia, Daiichi Sankyo Singapore, Daiichi Sankyo Mexico, and Daiichi Sankyo Colombia. In FY2025, Global excluded Daiichi Sankyo Mexico.
  • ＊12In FY2023, Global excluded Daiichi Sankyo Inc, Daiichi Sankyo Australia, Daiichi Sankyo Singapore, and Daiichi Sankyo Canada. In FY2024, Global excluded Daiichi Sankyo Inc., Daiichi Sankyo Australia, Daiichi Sankyo Singapore, Daiichi Sankyo Mexico, and Daiichi Sankyo Colombia. In FY2025, Global excluded Daiichi Sankyo Inc, and Daiichi Sankyo Mexico.
  • ＊13Number of total lost workhours due to work-related deaths and injuries / total hours worked × 1,000
  • ＊14Source: Survey by INTAGAE Healthcare Inc (Rep-i)
  • ＊15Global Health Innovative Technology Fund
  • ＊16Since FY2020, as a COVID 19 countermeasure, the facility has been opened only to a maximum of 10 visitors or 3 groups with reservations per day. Currently, the limit is a maximum of 20 people or 4 groups with reservations per day.

Corporate Governance

Ethics & Compliance

Training

Classification Boundary＊1 Items Unit FY2023 FY2024 FY2025
Compliance training Japan Total Persons 691 628 633
New employees Persons 217 247 315
Newly appointed managerial employees Persons 135 0 0
Newly appointed executive candidates Persons 98 110 110
Newly appointed vice presidents Persons 34 17 26
Mid-career hire employees Persons 207 254 182
Training on Daiichi Sankyo Group Employee Code of Conduct (e-learning and group training) Japan Persons 9,637 10,103 9,769
Outside Japan Persons 5,880 3,954 2,931
Information security training　Ratio of employees participating in e-learning Japan % 99.4 96.1 98.8
GVP＊2 training Non-consolidated GVP-related employees ％ 100 100 100
Persons 5,980 6,436 8,313
GQP＊3 training Non-consolidated GQP-related employees ％ 100 100 100

Survey

Classification Boundary＊1 Items Unit FY2023 FY2024 FY2025
Compliance awareness surveys Response rate Japan ％ 91.3 ー 90.0
Periodic employee survey on ethical culture Positive response rate Global ％ 86 93 93.4

Allegations

Classification Boundary＊1 Items Unit FY2023 FY2024 FY2025
Number of allegations received Reports Received Global Cases 315 363 376

Number of recalls

Classification Items Unit FY2023 FY2024 FY2025
Number of recalls (ClassI＊4) Global Cases 0 0 0
Number of recalls (ClassII＊5) Global Cases 2 3 7
 
 
 
  • ＊1Japan: Daiichi Sankyo (non-consolidated) and consolidated subsidiaries in Japan, Outside Japan: overseas consolidated subsidiaries, Global: Daiichi Sankyo (non-consolidated) and all its consolidated subsidiaries
  • ＊2Good Vigilance Practice: standards for safety management of post-marketing pharmaceuticals, quasi-pharmaceuticals, cosmetics, and medical devices
  • ＊3Good Quality Practice: a ministerial ordinance on quality management standards for pharmaceuticals, quasi-pharmaceuticals, cosmetics, and medical devices
  • ＊4A situation in which the use of or exposure to the product may severely affect the health or cause death
  • ＊5A situation in which the use of a product may cause temporary or medically reversible adverse health consequences or carries a minimal risk for serious adverse health effects.